Myovant Sciences (NYSE:MYOV) posted its quarterly earnings data on Thursday. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.06), Fidelity Earnings reports.
NYSE:MYOV opened at $19.06 on Friday. Myovant Sciences has a 12 month low of $11.30 and a 12 month high of $27.45. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.07 and a quick ratio of 3.07. The firm has a market cap of $1.46 billion, a PE ratio of -7.91 and a beta of 0.12.
In related news, Director Mark Altmeyer acquired 3,500 shares of the stock in a transaction dated Saturday, November 17th. The stock was acquired at an average cost of $13.38 per share, for a total transaction of $46,830.00. Following the completion of the purchase, the director now owns 3,500 shares of the company’s stock, valued at approximately $46,830. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 3.10% of the company’s stock.
MYOV has been the subject of several research reports. JPMorgan Chase & Co. initiated coverage on shares of Myovant Sciences in a research note on Thursday, September 13th. They set an “overweight” rating and a $39.00 price objective for the company. Zacks Investment Research upgraded shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Cowen reiterated a “buy” rating on shares of Myovant Sciences in a research note on Friday. Finally, Goldman Sachs Group initiated coverage on shares of Myovant Sciences in a research note on Friday, October 26th. They set a “neutral” rating and a $25.00 price objective for the company. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $29.20.
COPYRIGHT VIOLATION WARNING: This story was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://transcriptdaily.com/2018/11/10/myovant-sciences-myov-posts-quarterly-earnings-results-misses-expectations-by-0-06-eps.html.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Further Reading: How is an ETF different from a mutual fund?
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.